Ignite Creation Date:
2024-05-05 @ 4:57 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00352430
Status:
COMPLETED
Last Update Posted:
2019-09-25
First Post:
2006-07-13
Brief Title:
Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension
Sponsor:
National Heart Lung and Blood Institute NHLBI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Cardiopulmonary Function Assessment and NO Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension
Status:
COMPLETED
Status Verified Date:
2015-12-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate new treatments for people who have pulmonary hypertension or high blood pressure in the lungs caused by sickle cell anemia or thalassemia
Patients ages 18 and older with a diagnosis of sickle cell disease or thalassemia who have mild to severe pulmonary hypertension and who are not pregnant or breastfeeding may be eligible for this study There are three stages in the study with up to 200 participants in the screening Patients will undergo pulmonary function tests including those for asthma and measurement of oxygen levels in the arterial blood They will have a chest X-ray computed tomography CT scan of the lungs ventilation perfusion lung scan to look for blood clots echocardiogram test to measure how far patients can walk in 6 minutes nighttime oxygen measurement done while asleep blood collection magnetic resonance imaging MRI scan of the heart and exercise test About 3 to 4 days are needed for the tests all of which can be done while patients are outpatients except for the sleep study For the CT scan patients lie on a table while an X-ray beam takes images of the lungs and heart The lung scan involves breathing of a small amount of a radioactive aerosol called Tc99m DTPA while pictures are taken of the lungs from various angles Then an injection of albumin a protein with a small amount of radioactivity will be given and more lung pictures will be taken For the MRI scan patients lie on a table that slides into a machine A medication called gadolinium will be injected to help improve images made through the scan After the tests patients will be admitted to the Clinical Center for 1 day A small plastic catheter or tube will be placed in the vein of an arm A longer catheter will go into a deeper vein neck or leg and a pulmonary artery catheter will be inserted to measure blood pressure in the blood vessels Doctors will guide the catheter into the lung artery Patients will be asked to pedal on a stationary bicycle while heart and lung pressure is measured If pulmonary hypertension is present patients will proceed to the second stage up to 50 participants While the catheter is still in place patients will wear a face mask and breathe nitric oxide NO for 20 minutes They will take 50 mg of sildenafil by mouth and pressure in the heart and lungs will be monitored for about 4 hours They will again receive NO for another 20 minutes Blood samples will be taken and the heart rhythm and pressure in the lungs will be monitored Sildenafil can cause headache flushing and indigestion Side effects of the lung scan involve allergic reactions to DTPA and albumin Patients with an allergy to eggs should not have that test
Up to 25 patients can enter the third stage They will breathe NO by using a tank of gas that delivers it through tubes to the nose for a period of 6 weeks They will continue taking sildenafil as previously prescribed and visit the clinic every 2 to 4 weeks for an echocardiogram blood tests and 6-minute walk test After 6 weeks patients will have catheterization of the heart again to measure pressure in the heart and lungs Then NO will be stopped and pressure in the lungs will be checked to see if NO has helped lower the blood pressure-and to make sure that the blood pressure does not increase when medication is stopped Patients whose symptoms have improved as a result of breathing NO may wish to continue with that therapy
Patients ages 18 and older with a diagnosis of sickle cell disease or thalassemia who have mild to severe pulmonary hypertension and who are not pregnant or breastfeeding may be eligible for this study There are three stages in the study with up to 200 participants in the screening Patients will undergo pulmonary function tests including those for asthma and measurement of oxygen levels in the arterial blood They will have a chest X-ray computed tomography CT scan of the lungs ventilation perfusion lung scan to look for blood clots echocardiogram test to measure how far patients can walk in 6 minutes nighttime oxygen measurement done while asleep blood collection magnetic resonance imaging MRI scan of the heart and exercise test About 3 to 4 days are needed for the tests all of which can be done while patients are outpatients except for the sleep study For the CT scan patients lie on a table while an X-ray beam takes images of the lungs and heart The lung scan involves breathing of a small amount of a radioactive aerosol called Tc99m DTPA while pictures are taken of the lungs from various angles Then an injection of albumin a protein with a small amount of radioactivity will be given and more lung pictures will be taken For the MRI scan patients lie on a table that slides into a machine A medication called gadolinium will be injected to help improve images made through the scan After the tests patients will be admitted to the Clinical Center for 1 day A small plastic catheter or tube will be placed in the vein of an arm A longer catheter will go into a deeper vein neck or leg and a pulmonary artery catheter will be inserted to measure blood pressure in the blood vessels Doctors will guide the catheter into the lung artery Patients will be asked to pedal on a stationary bicycle while heart and lung pressure is measured If pulmonary hypertension is present patients will proceed to the second stage up to 50 participants While the catheter is still in place patients will wear a face mask and breathe nitric oxide NO for 20 minutes They will take 50 mg of sildenafil by mouth and pressure in the heart and lungs will be monitored for about 4 hours They will again receive NO for another 20 minutes Blood samples will be taken and the heart rhythm and pressure in the lungs will be monitored Sildenafil can cause headache flushing and indigestion Side effects of the lung scan involve allergic reactions to DTPA and albumin Patients with an allergy to eggs should not have that test
Up to 25 patients can enter the third stage They will breathe NO by using a tank of gas that delivers it through tubes to the nose for a period of 6 weeks They will continue taking sildenafil as previously prescribed and visit the clinic every 2 to 4 weeks for an echocardiogram blood tests and 6-minute walk test After 6 weeks patients will have catheterization of the heart again to measure pressure in the heart and lungs Then NO will be stopped and pressure in the lungs will be checked to see if NO has helped lower the blood pressure-and to make sure that the blood pressure does not increase when medication is stopped Patients whose symptoms have improved as a result of breathing NO may wish to continue with that therapy
Detailed Description:
Sickle cell anemia is an autosomal recessive disorder and the most common genetic disease affecting African-Americans Approximately 015 of African-Americans are homozygous for sickle cell disease and 8 have sickle cell trait Acute pain crisis acute chest syndrome ACS and secondary pulmonary hypertension are common complications of sickle cell anemia Pulmonary hypertension has now been identified as a major cause of death in adults with sickle cell disease Similarly pulmonary hypertension has been identified as a chronic complication of hemolytic disorders such as thalassemia hereditary spherocytosis and paroxysmal nocturnal hemoglobinuria Sildenafil has been proposed as a possible therapy for both primary and secondary pulmonary hypertension and recent phase III studies from the intramural NIH suggest it is well tolerated and efficacious in this population Furthermore a number of recent studies have suggested that NO based therapies may have a favorable impact on sickle red cells at the molecular level and could improve the abnormal microvascular perfusion that is characteristic of sickle cell anemia
This clinical trial is designed with three major objectives 1 to assess cardiopulmonary function in patients with sickle cell disease and thalassemia with and without pulmonary hypertension 2 to determine the relative acute vasodilatory effects of sildenafil and inhaled NO in patients with hemolysis-associated pulmonary hypertension and 3 to determine the chronic effects of the addition of inhaled NO on pulmonary hemodynamics and functional capacity in patients with hemolysis-associated pulmonary hypertension chronically treated with sildenafil
This clinical trial is designed with three major objectives 1 to assess cardiopulmonary function in patients with sickle cell disease and thalassemia with and without pulmonary hypertension 2 to determine the relative acute vasodilatory effects of sildenafil and inhaled NO in patients with hemolysis-associated pulmonary hypertension and 3 to determine the chronic effects of the addition of inhaled NO on pulmonary hemodynamics and functional capacity in patients with hemolysis-associated pulmonary hypertension chronically treated with sildenafil
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 06-H-0202 | None | None | None |